Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A liquid protein diet caused hair loss in a young woman.

Children with alopecia areata often face more stress and depression, especially related to separation, which can affect their condition.

This article discusses the growing trend of repurposing existing medications for innovative therapeutic uses and highlights the need for pharmacy practitioners to be informed about accessing clinical evidence related to these applications, but it reports no new results.

The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.

This study suggests that inhibitors of steroidogenic enzymes may have therapeutic potential for certain behavioral disorders linked to dopaminergic hyperfunction, despite concerns about their endocrine impacts.

This study reviewed reports on interactions between psychotropic drugs and natural beverages, finding that substances like grapefruit juice and St John's wort can significantly affect drug metabolism, emphasizing the need for physician-patient education on drug administration to prevent harmful interactions.

In this large multicenter study, severe hair loss related to psychotropic drug treatment was very rare but occurred more frequently in female patients, with valproic acid showing the highest risk.

This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.

This review focuses on neuroactive steroids' influence on GABA-ergic signaling and discusses challenges in developing them for various therapeutic uses, citing recent excitement from FDA approval of allopregnanolone for postpartum depression but reporting no new results.

This article discusses pharmacologic treatments for male sexual offenders, focusing on reducing sexual drive through nonhormonal or hormonal means, but it reports no new clinical results.

This review discusses the challenges of diagnosing and managing somatization in dermatology patients, highlighting the need for comprehensive evaluation of unexplained dermatologic symptoms, and reports no new results.

This study detected insomnia risk signals associated with various medications, primarily nervous system drugs, using the FDA's Adverse Event Reporting System data from 2004 to 2024.

This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.

This review discusses the challenges of diagnosing and treating pediatric bipolar disorder and highlights the potential benefits of combined psychopharmacological treatments, noting no long-term efficacy from mood stabilizer monotherapy.

This study found that opiate use was particularly associated with personality and behavioral disorders, while cannabis and legal highs were linked to psychotic disorders, and legal highs with schizophrenia.

This study highlights the need to examine the impact of lifestyle drugs on society, particularly focusing on usage patterns among youth and the general public.

This article reviews 12 newly approved drugs with pediatric indications from 2001, discussing their clinical importance for general pediatricians, but reports no new clinical results.

This article discusses drug repurposing as a strategy to find new uses for existing medications, highlighting its potential benefits like faster development and lower costs, while also addressing challenges such as drug specificity, ethical concerns, and regulatory issues.

This discussion reviews the shift in pharmaceutical strategy towards evidence-based and structure-guided drug development, highlighting ongoing challenges and efforts in computer-aided drug design without presenting new clinical results.

This review discusses how neurosteroids acting on GABAA receptors may influence behavior and explores the potential for developing selective modulators for treating psychiatric disorders, but reports no new clinical results.

This source redefines anti-aging medicine as "precision healthspan pharmacology," suggesting that rather than just treating diseases or accepting aging, pharmacology should focus on expanding functional capacity across various health domains, while emphasizing the importance of fundamental physiological and psychosocial health factors.

This chapter discusses phase transitions in various pharmaceutical examples and does not present any new research findings.

This review explores how psychotropic medications can cause a range of skin reactions, from mild to life-threatening, and emphasizes the importance of monitoring for these adverse effects early in treatment.

Different medications can cause serious side effects in some people.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This study developed a new clustering model to improve detection of drug-induced cognitive disorder risk signals, finding that it identified drugs with moderate risk signals, like Carbidopa/Levodopa, missed by traditional methods, enhancing clinical assessment comprehensiveness.